|
Accueil > Actualité
AstraZeneca: asthma drug fails Phase 2 trial
(CercleFinance.com) - AstraZeneca's AZD1419, a new approach for the treatment of asthma, has failed in a Phase 2 clinical trial to improve asthma control, the drugmaker's US partner Dynavax said on Friday.
According to initial results from the trial, the treatment was not associated with a statistically significant improvement in the time to loss of asthma control, Dynavax said. Therefore it did not meet the study's primary endpoint, it said. AZD1419 is an investigational TLR9 agonist that is developed by Dynavax, in collaboration with AstraZeneca. Dynavax said AstraZeneca now plans to review the full data before deciding on the next steps for the program. Copyright (c) 2018 CercleFinance.com. All rights reserved. |
19/04/2024 08:42
Pluxeerelèvement des objectifs annuels 19/04/2024 08:18 Sodexohausse de 46% du résultat net ajusté au 1er semestre 19/04/2024 08:00 Spieacquisition d'ICG Group finalisée en Allemagne 19/04/2024 07:42 Argandividende versé à près de 28% en actions 19/04/2024 07:25 Mercialyshausse de 4,5% des loyers au 1er trimestre 19/04/2024 07:08 Viel & Cieannulation de 1,82 million d'actions Tous les articles sociétés |
